首页> 美国卫生研究院文献>ESMO Open >Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature

【2h】

Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature

机译：达卡巴嗪对MAGE-A3阳性转移性皮肤黑色素瘤患者进行MAGE-A3癌症免疫治疗的安全性和免疫原性：I / II期开放性研究首次评估了预测性基因特征

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundWe assessed safety, immunogenicity and clinical activity of recombinant MAGE-A3 antigen combined with AS15 immunostimulant (MAGE-A3 immunotherapeutic) in association with dacarbazine in patients with metastatic melanoma.

机译：背景我们评估了转移性黑素瘤患者中重组MAGE-A3抗原联合AS15免疫刺激剂（MAGE-A3免疫治疗）联合达卡巴嗪的安全性，免疫原性和临床活性。

著录项

期刊名称 ESMO Open
作者
Jean-Jacques Grob; Laurent Mortier; Lionel D’Hondt; Florent Grange; Jean Francois Baurain; Brigitte Dréno; Céleste Lebbe; Caroline Robert; Anne Dompmartin; Bart Neyns; Marc Gillet; Jamila Louahed; Silvija Jarnjak; Frédéric F Lehmann;
展开▼
作者单位

展开▼
年(卷),期 2017(2),5
年度 2017
页码 e000203
总页数 8
原文格式 PDF
正文语种
中图分类
关键词
immunotherapy melanoma;

机译：免疫疗法;黑色素瘤;

相似文献

外文文献
专利

1. Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer [J] . Pujol Jean-Louis, Vansteenkiste Johan F., De Pas Tommaso Martino, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2015,第10期

机译：IB期至III期MAGE-A3阳性非小细胞肺癌患者的MAGE-A3免疫治疗或不进行辅助化学疗法的安全性和免疫原性
2. Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT) [J] . Saiag P., Gutzmer R., Ascierto P. A., Annals of oncology: official journal of the European Society for Medical Oncology . 2016,第10期

机译：对MAGE-A3免疫治疗（PREDICT）后转移性黑色素瘤患者的临床预测的基因标志的潜在评估
3. Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT) [J] . Saiag P., Gutzmer R., Ascierto P. A., Annals of oncology: official journal of the European Society for Medical Oncology . 2016,第10期

机译：对Mage-A3免疫治疗（预测）后转移性黑素瘤患者临床益处临床益处的前瞻性评估
4. Preliminary results of a phase I/II clinical trial using in situ photoimmunotherapy combined with imiquimod for metastatic melanoma patients [C] . Xiaosong Li, Mark F. Naylor, Robert E. Nordquist, . 2010

机译：使用原位光免疫疗法联合咪喹莫特治疗转移性黑色素瘤患者的I / II期临床试验的初步结果
5. Blocking immunosuppressive factors and taking advantage of the nutrient supply within the tumor microenvironment: Pathways to achieve improved cancer immunotherapeutic efficacy for patients with metastatic melanoma [D] . Zhang, Ying. 2016

机译：阻断免疫抑制因子并利用肿瘤微环境内的营养供应：途径，以实现转移性黑素瘤患者的改善癌症免疫治疗疗效
6. Prospective assessment of a gene signature potentially predictive of clinical benefit in metastatic melanoma patients following MAGE-A3 immunotherapeutic (PREDICT) [O] . P. Saiag, R. Gutzmer, P. A. Ascierto, -1

机译：对MAGE-A3免疫治疗（PREDICT）后转移性黑色素瘤患者的临床预测的基因签名的潜在评估
7. Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer [O] . Pujol Jean-Louis, Vansteenkiste Johan F., Pas Tommaso Martino De, 2015

机译：IB期至III期MAGE-A3阳性非小细胞肺癌患者的MAGE-A3免疫治疗与辅助化疗的安全性和免疫原性

Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature

摘要

著录项

相似文献

相关主题

期刊订阅